TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Autologous Cultured Adipose -Derived Stem Cells for the Fecal Incontinence

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Older than 18 years~* Wexner's fecal incontinence score \> or egal 5~* patient who has fecal incontinence for more than 6 months~* Continuity of anal sphincter at endorectal ultrasound and abnormality of anal function at anorectal manometry~* negative for urine beta-HCG for woman of childbearing age~* agreement to participate, with signed informed-consent~Exclusion Criteria:~* Anorectal surgery within the last 6 months prior to the study~* patient who is allergy to bovine-derived materials and an anesthetic~* patients with a diagnosis of auto immune disease~* Diagnosis of HBV, HCV, HIV and other infectious disease~* Patients with a diagnosis of active Tuberculosis~* Patient is pregnant or breast-feeding~* Women within 6 months post partum~* Patient who is unwilling to use an effective method of contraception during the study~* Patients with a diagnosis of Inflammatory Bowel Disease~* Patient who has a clinically relevant history of abuse of alcohol or drugs~* Insufficient adipose tissue for manufacturing of ANT-SM~* Patient whom investigator consider is not suitable in this study~* Patients have history of surgery for malignant cancer in the past 5 years~* Patient who has to undergo ano-rectal surgery~* Patient who has a history of artificial anal sphincter surgery~* Patient who has taken cytotoxic drugs within the last 30 days~* Patient whom investigator consider is not suitable in this study reasons for severe ano-rectal disease, severe constipation, fistula, rectal prolapsed or neurological diseases (spinal cord injury, multiple sclerosis, Parkinson's disease)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ANT-SM (Type: EXPERIMENTAL): autologous adipose-derived stem cell

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Active cocaine dependence with at least 8 days of use or at least 4 binges of large amounts (\>$200/occasion) over the past 30 days, and displaying at least one positive utox during screening~* Physically healthy~* No adverse reactions to study medications~* 21-60 years of age~* Capacity to consent and comply with study procedures, including sufficient proficiency in English~* Seeking treatment~Exclusion Criteria:~* Meets DSM IV criteria for current major depression, bipolar disorder, schizophrenia, any psychotic illness, including substance induced psychosis, and current substance-induced mood disorder with HAMD score \> 12.~* Physiological dependence on another substance requiring medical management, such as alcohol, opioids, or benzodiazepines, excluding caffeine, nicotine, and cannabis~* Delirium, Dementia, Amnesia, Cognitive Disorders, or Dissociative disorders~* Current suicide risk or a history of suicide attempt within the past year~* Pregnant or interested in becoming pregnant during the study period~* Heart disease as indicated by history, abnormal ECG, previous cardiac surgery.~* Unstable physical disorders which might make participation hazardous such as end-stage AIDS, hypertension (\>140/90), WBC \< 3.5, active hepatitis or other liver disease with elevated transaminase levels (\< 2-3 X upper limit of normal will be considered acceptable if PT/PTT is normal), renal failure (creatinine \> 2, BUN \>40), or untreated diabetes~* Previous history of ketamine or benzodiazepine misuse or abuse, and a history of an adverse reaction/experience with prior exposure to ketamine or benzodiazepine~* Recent history of significant violence (past 2 years)~* First degree relative with a psychotic disorder (bipolar disorder, schizophrenia, schizoaffective disorder, or psychosis NOS)~* BMI \> 32, or a history of documented obstructive sleep apnea~* On psychotropic or other medications whose effect could be disrupted by participation in the study~* Patients who cannot comply with study procedures during the initial hospitalization phase

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): 0.5 mg/kg of ketamine IV over 40 minutes
- midazolam (Type: ACTIVE_COMPARATOR): 0.025 mg/kg IV over 40 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Improving Communication With Patients With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of breast cancer~PATIENT CHARACTERISTICS:~* Patients: 30 to 80 years of age~* Family members: 20 to 80 years of age~* Healthcare team members: 20 to 80 years of age~* Must be conversant in English~PRIOR CONCURRENT THERAPY:~* Not specified

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Elective Lymph Node Treatment Versus Clinical Observation in the Absence of Palpable Lymph Nodes for High Risk Skin Squamous Cell Carcinoma (SCC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Major criterion and at least one minor criteria~* Major criterion: \> 6 mm depth of invasion~* Minor criteria (one or more):~* Greater than 2cm diameter~* Recurrent (prior Mohs, wide local excision, electrodesiccation and curettage, topical imiquimod or 5 fluorouracil, cryotherapy or photodynamic therapy)~* High risk location: any portion of cutaneous lip, ear, temple, scalp~* Immunosuppressed host (organ transplant recipient or chronic lymphocytic leukemia)~* Perineural invasion (yes/no; nerve involved must be greater than 0.1mm)~* Direct involvement of subcutaneous tissue (Clark's V), muscle, cartilage,or bone~Exclusion Criteria:~* Satellite metastases~* Clinically abnormal lymph node exam~* Location other than head or neck~* Exclusively mucosal squamous cell carcinoma~* Previous head and neck radiation~* In situ disease, keratoacanthoma subtypes, metatypical or collision tumors~* Inability of subject to give written informed consent~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Elective lymph node treatment arm (Type: ACTIVE_COMPARATOR): Patients entering this arm will undergo selective nodal dissection of the draining lymph nodes with subsequent radiation and/or chemotherapy if indicated.
- Clinical observation arm (Type: NO_INTERVENTION): Patients who enter into this arm will undergo regular, periodic clinical nodal observation with subsequent evaluation and treatment if indicated upon discovery of a palpable lymph node.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pentoxifylline Therapy in Biliary Atresia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 0-180 days old~* Diagnosed with biliary atresia through liver biopsy and/or intra-operative cholangiogram~* No previous Kasai portoenterostomy performed at another institution~* Able to take medications orally~* Legal guardian signs consent after understanding risks and investigational nature of study~Exclusion Criteria:~* Infants greater than 180 days old~* Infants receiving a Kasai portoenterostomy at another institution~* Infants unable to take medications orally

- Gender: ALL
- Minimum Age: None
- Maximum Age: 180 Days
- Healthy Volunteers: f

Study Arms:
- Pentoxifylline (Type: EXPERIMENTAL): All newly-diagnosed biliary atresia patients fulfilling the study's inclusion criteria will receive oral pentoxifylline, 20 mg/kg/day divided in three doses for a total of 90 days.~The hospital pharmacy will create a 20 mg/ml oral pentoxifylline solution using 400 mg pentoxifylline tablets and established compounding recipes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing Efficacy of HM3 Versus F2 Lithotripters for Stone Fragmentation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients diagnosed with urolithiasis and choose to have ESWL treatment~2. Age 18-90 years old~3. Able to understand the informed consent~Exclusion Criteria:~1. Minors~2. Cognitively impaired

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Using HM3 lithotripter (Type: ACTIVE_COMPARATOR): This is an older generation lithotripter
- F2 lithotripter (Type: ACTIVE_COMPARATOR): This is a newer generation lithotripter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Incidence of Acute Kidney Injury After Laparoscopic Cholecystectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age \> 18 years, able to sign the consent form, stable kidney function.~Exclusion Criteria:~* end stage renal disease~* acute kidney injury or need of dialysis three months prior the procedure~* acute infection~* acute inflammation~* malignancy~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of parkinsonism (idiopathic PD, multiple systems atrophy, Lewy body dementia)~* RBD frequency of at least once per week based on the RBD screening clinical questionnaire~* PSG evidence of RBD~* Presence of bed partner/caregiver who sleeps in the same room as PD patient~Exclusion Criteria:~* Known hypersensitivity to ramelteon or related compounds, including melatonin and melatonin-related compounds.~* Use of hypnotics or other sedatives within a month prior to the study initiation~* Presence of active psychosis~* Use of neuroleptics, except for the atypical neuroleptics - specifically quetiapine (the dose should not exceed 50mg/day)~* Use of antidepressants unless the patient has been on a stable dose for at least three months~* Use of Venlafaxine (Effexor®)~* Presence of cognitive impairment, defined as the Mini Mental Status Examination (MMSE) score \<24~* Presence of depression defined as the Beck Depression Inventory (BDI) score \>14~* Significant sleep disordered breathing (defined as an apnea-hypopnea index\>15 events/hr of sleep on screening PSG), significant periodic limb movement disorder (defined as a PLM index\>10 events/hr of sleep with awakening on screening PSG)~* Travel through two time zones within a month prior to the study initiation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Ramelteon (TAK-375) 8mg tablets
- 2 (Type: PLACEBO_COMPARATOR): Placebo 8 mg tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Liquorice on Plasma Potassium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy volunteers~* age 18-40~Exclusion Criteria:~* any continuous medication~* hypertension or hypotension~* allergy to liquorice~* pregnancy or lactation~* difficult venipuncture~* drug or alcohol abuse~* participation in pharmaceutical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Liquorice 66 g/day (Type: ACTIVE_COMPARATOR): Liquorice given 66 grams per day for two weeks
- Liquorice 102 g/day (Type: ACTIVE_COMPARATOR): Liquorice given 102 grams per day for two weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Mobile Phone Technology for Chronic Pain Patients- A Feasibility Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with eligible smart phone devices (iPhones and Androids- working, newer models (released in the last 3 years)) running a sufficient, current version of iOS or Android~* Chronic low back pain (at least 3 months) with or without lower extremity pain (i.e. lumbar radiculopathy, spinal stenosis)~* Average pain is rated at least moderate (numerical score greater than or equal to 5/10)~* Ages 18 - 65 years~* Participating in Chronic Pain Registry (standard of care)~Exclusion Criteria:~* Conditions limiting mobility~* Non-ambulatory (wheelchair bound)~* Movement or neuromuscular disorders~* Significant lower extremity weakness~* Severe cardiorespiratory disease~* Moderate to severe cognitive impairment~* Active cancer therapy (chemotherapy or radiation) in the last year~* Major surgery in the last 3 months~* Inability to comply with study requirements per investigator judgement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Outpatients (Type: None): Outpatients enrolled in this study are required to complete study assessments on mobile applications and through questionnaires. A daily electronic diary will be completed through the Ohmage app. The Mobility app will be used to track the patients' movement and activity. Patients will be administered a questionnaire at the 1 and 2 week endpoints.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Apremilast in the Treatment of Uveitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with vision-threatening autoimmune uveitis~* failure to respond to prednisone and at least one other systemic immunosuppressive, or intolerance to such medications due to side effects~Exclusion Criteria:~* serious concomitant illness that could interfere with the subject's participation~* previous or current use of an alkylating agent~* use of CYP3A4 inhibitors during the trial~* TNF blocker use within the 8 weeks prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Patients receiving apremilast.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female 12-70 years of age (inclusive).~2. Diagnosis of asthma for at least 6 months.~3. Morning FEV1 of 40-80% normal.~4. Demonstrated reversible airflow restriction.~5. Non-smokers.~6. On moderate doses of ICS with inadequate asthma control.~7. Signed ICF~Exclusion Criteria:~1. Diagnosis of COPD.~2. Uncontrolled systemic illness.~3. Hypersensitivity to any component of ZYFLO CR~4. Any patient with an unscheduled visit to an ER or hospital for asthma exacerbation within past 3 months.~5. History of hepatitis or active liver disease.~6. ALT greater than 3xULN.~7. History of HIV infection~8. Recent history of drug or alcohol abuse.~9. Oral corticosteroids within one month, cromolyn sodium or nedocromil within 14 days, theophylline, LABA, ZYFLO, or leukotriene modifiers, warfarin or propranolol, inhaled anti-cholinergics, or combination LABA/ICS.~10. Omalizumab within 3 months.~11. Pregnant female.~12. Participation with 30 days in investigational study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Zileuton CR
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Saliva for Alzheimer's Disease Diagnosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men/Women;~* Aged ≥ 55 years and 80 years;~* Patients mild cognitive impairment (MCI), not answering either the criteria of a normal cognitive functioning or the criteria of the insanity, but meeting the criteria of diagnosis of following MCI in the term of a complete cognitive balance sheet (assessment) and according to the diagnostic procedure published by the work group on the MCI of the EADC:~  * Mnesic complaint~ * Decline of the cognitive performances with regard to the previous capacities~ * Cognitive disorders(confusions) objectified by the clinical evaluation (change of the memory and/or another cognitive sphere)~ * The cognitive change has no echo on the everyday life~ * Not dementia syndrome~* Signature of the informed consent by the patient;~* Subject affiliated to a national insurance scheme.~Exclusion Criteria:~* Edentulous total or poor oral hygiene;~* Absence of the signed informed consent;~* Clinical and laboratory information insufficient or unavailable;~* Patient deprived of freedom, by court or administrative order;~* Major protected by law;~* Presence of a contagious viral affection (HIV, hepatitis B and C);~* Patient included in a therapeutic trial targeting the metabolism of metabolism of amyloid peptides ;~* Patient in period of relative exclusion with regard to another protocol or for which the annual maximum amount of the 4500-compensations was reached.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Patients with Alzheimer disease (Type: OTHER): Saliva samples were collected on this patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Possible Influence of Different Follow-up Modalities on Overall Survival in Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women aged ≥ 18 years~* Between diagnosis and the first follow-up visit after the end of their antineoplastic treatment (systemic therapy or surgical treatment) for ovarian cancer.~* German, English, French, or Italian speaking~* Personal smartphone (iOS or Android system); one of the latest three main versions~Exclusion Criteria:~• Patients whose compliance must be questioned, e.g. due to a psychiatric disorder, private life situation or insufficient knowledge on smartphone use and do not have a suitable caregiver to assist them with symptom reporting.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues